In 2019, the ER‐targeted PROTAC ARV‐471 developed by Crews group and Arvinas, Inc. was approved by the US FDA as an investigational new drug for the treatment of locally advanced or metastatic ER‐positive/HER2‐negative breast cancer.46 The gene discussed is ESR1; the disease is breast carcinoma.